Application | Comment | Organism |
---|---|---|
medicine | combination of (2E)-2-(anthracen-9-ylmethylidene)-N-hydroxyhydrazinecarboximidamide with the first-line antileukemic agent arabinofuranosylcytosine, Ara-C, synergistically potentiates the antineoplastic effects of Ara-C | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(2E)-2-(anthracen-9-ylmethylidene)-N-hydroxyhydrazinecarboximidamide | i.e. ABNM-13, application leads to significant alterations of deoxyribonucleoside triphosphate pool balance and a highly significant decrease of incorporation of radiolabeled cytidine into DNA of HL-60 cells. Diminished ribonucleotide reductase activity causes replication stress which is consistent with activation of Chk1 and Chk2, resulting in downregulation/degradation of Cdc25A. Cdc25B is upregulated, leading to dephosphorylation and activation of Cdk1. The combined disregulation of Cdc25A and Cdc25B is the most likely cause for ABNM-13 induced S-phase arrest | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
HL-60 cell | promyelocytic leukemia cell | Homo sapiens | - |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.011 | - |
pH not specified in the publication, temperature not specified in the publication | Homo sapiens | (2E)-2-(anthracen-9-ylmethylidene)-N-hydroxyhydrazinecarboximidamide |